Emergence of fluoroquinolone-resistant tuberculosis in New York City

E. A. Sullivan, L. Palumbo, A. Ebrahimzadeh, T. R. Frieden, E. A. Sullivan, T. R. Frieden, B. N. Kreiswirth, V. Kapur, James M. Musser

Research output: Contribution to journalArticle

112 Scopus citations

Abstract

22 patients infected with fluoloquinolone-resistant Mycobacterium tuberculosis in New York City were identified between January, 1991, and November, 1993. In 16 patients resistance arose as a result of inadequate or inappropriate treatment. 6 patients had primary infection with fluoroquinolone-resistant organisms; 5 acquired the organisms nosocomially. Seven distinct patterns of restriction-fragment length polymorphism were identified in isolates from 21 patients. Fluoroquinolones should be restricted to patients with multidrug-resistant disease or intolerance to other antituberculosis drugs. All patients with multidrug-resistant tuberculosis should be on directly observed therapy.

Original languageEnglish (US)
Pages (from-to)1148-1150
Number of pages3
JournalThe Lancet
Volume345
Issue number8958
DOIs
StatePublished - May 6 1995

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Emergence of fluoroquinolone-resistant tuberculosis in New York City'. Together they form a unique fingerprint.

Cite this